Late Peaks of HMGB1 and Sepsis Outcome: Evidence For Synergy With Chronic Inflammatory Disorders

Shock
Eleni KarakikeI Tsangaris

Abstract

High mobility group box 1 (HMGB1) is released from macrophages as a late biomarker of sepsis. Conditions associated with pre-existing macrophage activation may modify HMGB1 expression. This study aimed to assess the impact of HMGB1 kinetics on 28-day mortality. In a sub-study of a previous randomized clinical trial among patients with systemic inflammatory response syndrome and gram-negative infections, patients were classified in early and late HMGB1 peak groups. Serial measurements of HMGB1, ferritin and interferon-gamma (IFNγ) were performed in all available sera. Two hundred ten patients were included; 118 (46.5%) had at least one inflammatory disease (diabetes, chronic obstructive pulmonary disease, chronic heart failure, or chronic renal disease). Mortality after 28 days was higher among patients with a late peak of HMGB1 (OR 2.640; P = 0.026). Co-existence of late peak and inflammatory disease synergistically impacted mortality (odds ratio of logistic regression analysis 3.17; P: 0.027). Late peak was concomitantly associated with higher values of ferritin (P = 0.035), and IFNγ (P = 0.002) among patients with hyperferritinemia. It is concluded that late HMGB1 peak was associated with worse prognosis, especially in patien...Continue Reading

References

Jul 10, 1999·Science·H WangK J Tracey
Apr 20, 2004·Critical Care Medicine·R Phillip DellingerUNKNOWN Surviving Sepsis Campaign Management Guidelines Committee
Mar 9, 2005·Critical Care Medicine·Jonas Sundén-CullbergCarl Johan Treutiger
May 26, 2007·Intensive Care Medicine·Sébastien GibotPierre-Edouard Bollaert
Feb 26, 2008·Intensive Care Medicine·Sari KarlssonEsko Ruokonen
Aug 13, 2010·Basic Research in Cardiology·H Christian VolzMartin Andrassy
Feb 2, 2012·Nature Reviews. Rheumatology·Helena Erlandsson HarrisDavid S Pisetsky
Dec 3, 2013·The Journal of Antimicrobial Chemotherapy·Evangelos J Giamarellos-BourboulisApostolos Armaganidis
Feb 1, 2014·Expert Opinion on Therapeutic Targets·Lori F Gentile, Lyle L Moldawer
Jun 18, 2014·Journal of Internal Medicine·A TsungT R Billiar
Jul 11, 2014·Molecular Aspects of Medicine·Rui KangDaolin Tang
Sep 30, 2014·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·Jaruek CharoensupSurasakdi Wongratanacheewin
Jan 23, 2016·Mediators of Inflammation·Sebastiano GangemiEgidio Imbalzano
Feb 24, 2016·JAMA : the Journal of the American Medical Association·Mervyn SingerDerek C Angus
Jun 18, 2017·Molecular and Cellular Endocrinology·Jing ZhangPing Yang
Aug 29, 2017·The New England Journal of Medicine·Paul M RidkerUNKNOWN CANTOS Trial Group

❮ Previous
Next ❯

Citations

Aug 14, 2019·Shock·Feng WuRosemary A Kozar
Apr 9, 2020·Frontiers in Immunology·Huan YangUlf Andersson
May 31, 2021·Journal of Cosmetic Dermatology·Rehab Mohammed SalemRasha Shaker

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biomarkers for Diabetes

This feed focuses on the latest research on biomarkers used for monitoring disease progression in diabetes.

Related Papers

Critical Care Medicine
Huan Yang, Kevin J Tracey
Hua xi kou qiang yi xue za zhi = Huaxi kouqiang yixue zazhi = West China journal of stomatology
Huaqiang ZhaoPishan Yang
Zhongguo wei zhong bing ji jiu yi xue = Chinese critical care medicine = Zhongguo weizhongbing jijiuyixue
Wei DangXiao-dong Zhao
© 2022 Meta ULC. All rights reserved